

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 29 2006

ART UNIT: (not yet assigned) 11

EXAMINER: (not yet assigned)

Application of:

Denise L. Faustman

Serial No.:

09/673,292

Filed:

October 13, 2000

Entitled:

TRANSPORT ASSOCIATED PROTEIN

SPLICE VARIANTS AND MODEL FOR

IMMUNE DIVERSITY

Attorney Docket No. MGH-002.1P US/MGH-1247.0

Asst. Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:

Transmitted herewith are: [X] An Information Disclosure Statement (IDS) under 37 CFR §§ 1.56, 1.97 and 1.98; [X] Form PTO-1449 Information Disclosure Statement; [X] A photocopy of each reference cited; and [X] a return receipt post card.

PAYMENT OF FEES

- A check in the amount of \$_____in payment of the fee for submission of an information disclosure statement transmitted herewith.
- [X] The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR §§ 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Leon R Yankwich; Registration No. 30,237

Kenneth P. Zwicker, PhD; Registration No. 43,310

Attorneys for Applicants

YANKWICH & ASSOCIATES

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

telephone: (617) 491-4343 telefax: (617) 491-8801

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as Priority Mail postage prepaid, in an envelope addressed to the Asst. Commissioner for Patents, Washington, DC 20231, on the date indicated below.

<u>mber 17, 20</u>00

Date

Stephanie L. Leicht



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 29 2009

TECH CENTER 1600/2906

ART UNIT: (not yet assigned)

EXAMINER: (not yet assigned)

plication of:

Denise L. Faustman

Serial No.:

09/673,292

Filed:

October 13, 2000

Entitled:

TRANSPORT ASSOCIATED PROTEIN

SPLICE VARIANTS AND MODEL FOR

IMMUNE DIVERSITY

Attorney Docket No. MGH-002.1P US

Asst. Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A modified Form PTO-1449 listing the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list. Pursuant to 37 C.F.R. § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

US Patent Documents:

U.S. 4,946,778, issued August 7, 1990 (Ladner et al.)

U.S. 5,538,854, issued July 23, 1996 (Faustman)

Foreign Patent Documents:

WO 92/11289 A1, published July 9, 1992 (Trowsdale et al.)

Other Publications:

Androlewicz et al., Proc. Natl. Acad. Sci. USA, 91(26): 12716-12720 (1994);

Attaya et al., Nature, 355: 647 (1992);

Bahram et al., Proc. Natl. Acad. Sci. USA, 88: 10094-10098 (1991);

Beck et al., J. Mol. Biol., 228: 433-441 (1992);

Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 (1985);

Daniel et al., J. Immunol., 159: 2350-2357 (1997)

Faustman et al., Science, 254: 1756-1761 (1991);

Fu et al., J. Clin. Invest., 91: 2301 (1993);

Hill et al., Proc. Natl. Acad. Sci. USA, 92: 341-343 (1995);

Howard., Proc. Natl. Acad. Sci. USA, 90: 3777-3779 (1993);

Kohler and Milstein, *Nature*, 256: 495-497 (1975);

Kozbor et al., Immunology Today, 4: 72 (1983);

Momburg et al., Nature, 367: 648 (1994);

Momburg et al., J. Exp. Med., 179: 1613 (1994)

Neefjes et al., Science, 261: 769 (1993);

Neefjes et al., Eur. J. Immunol., 25: 1133 (1995);

Obst et al., Eur. J. Immunol., 25: 2170-2176 (1995);

Ortmann et al., Nature, 368: 864 (1994);

Powis et al., J. Exp. Med., 173: 913 (1991);

Powis et al., Nature, 357: 211-215 (1992);

Powis et al., Immunogenetics, 37: 373-380 (1993);

Powis et al., Immunity, 4(2): 159-165 (1996);

Schumacher et al., Proc. Natl. Acad. Sci. USA, 91(26): 13004-13008 (1994);

Spies and DeMars, Nature, 351: 323 (1991);

Wang et al., Human Gene Therapy, 6: 1005-10017 (1995).

There is no intention on the part of Applicant to indicate by the listing above that any of the foregoing documents is material to the patentability of the claimed invention.

Applicant requests that each of the publications listed above be considered and made of record in the present application.

Respectfully submitted,

Leon R. Yankwich, Registration No. 30,237

Kenneth P. Zwicker, Ph.D., Registration No. 43,310

Attorneys for Applicant Yankwich & Associates

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

Phone: (617) 491-4343 Facsimile: (617) 491-8801

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as Priority mail, postage prepaid, in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

date of mailing and signature

Stephanie L. Leicht

Modi			

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO	RECE	VED
MGH-002.1P US	09/673,292	DEC 29	
APPLICANT	•		2000
D. Faustman		TECH CENTER	 600/290(
FILING DATE	GROUP		

not yet assigned

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

October 13, 2000

			<u> </u>	FAILNI DOC	CINICIAIO		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	U.S. 4,946,778	8/7/90	Ladner et al.			
	AB	U.S. 5,538,854	7/23/96	Faustman			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TRANSI YES	ATION NO
	AC	WO 92/11289	7/9/92	Trowsdale et al.				
-								

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)					
	AD	Androlewicz et al., <u>Proc. Natl. Acad. Sci. USA</u> , 91(26): 12716-12720 (1994);					
	AE	Attaya et al., Nature, 355:647 (1992);					
	AF	Bahram et al., Proc. Natl. Acad. Sci. USA, 88: 10094-10098 (1991);					
	AG Beck et al., J. Mol. Biol., 228: 433-441 (1992);						
	АН	Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 (1985);					
	Al Daniel et al., <u>J. Immunol.</u> , 159: 2350-2357 (1997)						
	AJ	Faustman et al., Science, 254:1756-1761 (1991);					
	AK	Fu et al., <u>J. Clin. Invest.</u> , 91:2301 (1993);					
EXAMINER	1	DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Modified FORM PTO-1449 - CONT'D	ATTY. DOCKET NO.	SERIAL NO.
•	MGH-002.1P US	09/673,292
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT	
STATEMENT	D. Faustman	
(Use several sheets if necessary)	FILING DATE	GROUP
	October 13, 2000	not yet assigned

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	Hill et al., Proc. Natl. Acad. Sci. USA, 92: 341-343 (1995);
	AM	Howard., Proc. Natl. Acad. Sci. USA, 90: 3777-3779 (1993);
	AN	Kohler and Milstein, Nature, 256:495-497 (1975);
	AO	Kozbor et al., Immunology Today, 4:72 (1983);
	AP	Momburg et al., <u>Nature</u> , 367:648 (1994);
	AQ	Momburg et al., <u>J. Exp. Med.</u> , 179:1613 (1994)
	AR	Neefjes et al., Science, 261:769 (1993);
	AS	Neefjes et al., Eur. J. Immunol., 25:1133 (1995);
•	AT	Obst et al., Eur. J. Immunol., 25: 2170-2176 (1995);
	AU	Ortmann et al., Nature, 368:864 (1994);
	AV	Powis et al., <u>J. Exp. Med.</u> , 173:913 (1991);
	AW	Powis et al., Nature, 357:211-215 (1992);
	AX	Powis et al., <u>Immunogenetics</u> , 37:373-380 (1993);
	AY	Powis et al., <u>Immunity</u> , 4(2):159-165 (1996);
-	AZ	Schumacher et al., Proc. Natl. Acad. Sci. USA, 91(26):13004-13008 (1994);
	ВА	Spies and DeMars, <u>Nature</u> , 351:323 (1991);
	ВВ	Wang et al., Human Gene Therapy, 6: 1005-10017 (1995).
EXAMINER	1	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.